ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 0411

Pharmacokinetics, Safety, and Efficacy of Subcutaneous Brodalumab for Systemic Sclerosis with Moderate-to-severe Skin Thickening: A Single-arm, Open-label, Multi-dose, Phase 1 Trial

Takemichi Fukasawa1, Ayumi Yoshizaki2, Satoshi Ebata2 and Shinichi Sato2, 1Department of Dermatology, The University of Tokyo, Graduate School of Medicine, Tokyo, Japan, 2University of Tokyo Graduate School of Medicine, Tokyo, Japan

Meeting: ACR Convergence 2021

Keywords: autoimmune diseases, Brodalumab, clinical trial, IL-17, Scleroderma, Systemic

  • Tweet
  • Email
  • Print
Session Information

Date: Saturday, November 6, 2021

Session Title: Systemic Sclerosis & Related Disorders – Clinical Poster I (0387–0413)

Session Type: Poster Session A

Session Time: 8:30AM-10:30AM

Background/Purpose: The exact role of interleukin-17 in systemic sclerosis (SSc) has not been established. This trial assessed the pharmacokinetics (PK), safety, and efficacy of multiple subcutaneous doses of brodalumab 210 mg administered every 2 weeks in Japanese SSc patients with moderate-to-severe skin thickening.

Methods: In this open-label, multiple-dose, phase 1 study, eligible patients received 52‑week treatment. Primary endpoints were PK and safety. Secondary endpoints included change from baseline in the modified Rodnan Skin Score (mRSS) and Composite Response Index in Systemic Sclerosis (CRISS) score. Exploratory endpoints included lymphocyte subset testing.

Results: Eight patients were enrolled. Mean (SD) age was 53.6 (10.6) years, total mRSS was 23.1 (5.1), and SSc disease duration was 2.2 (1.9) years. Mean (SD) serum brodalumab trough concentration increased to 21.8 (16.7) μg/mL at week 2 and remained almost constant at week 52. Drug-related treatment-emergent adverse events were observed in three patients: oral candidiasis (n=3), vulvovaginal candidiasis (n=1), and arthralgia (n=1). A rapid and significant decrease in mRSS was observed as early as week 4 (p< 0.005), which continued until week 52 (p< 0.0001). At week 52, all patients achieved a CRISS score ≥0.6. The Th17/Treg balance showed a significant sustained Treg dominance over 52 weeks (p< 0.05). The significant decrease in the number of immunoglobulin G+ class-switched memory B cells and plasmablasts (p< 0.01) was accompanied by a significant increase in the number of transitional B cells (p< 0.05) by week 52.

Conclusion: Brodalumab demonstrated a rapid, sustained, and significant decrease in mRSS over 52 weeks in Japanese SSc patients with moderate-to-severe skin thickening, which could be attributed to its direct effects on fibroblasts and indirect effects via impacts on B and T cell subsets.


Disclosures: T. Fukasawa, None; A. Yoshizaki, None; S. Ebata, None; S. Sato, None.

To cite this abstract in AMA style:

Fukasawa T, Yoshizaki A, Ebata S, Sato S. Pharmacokinetics, Safety, and Efficacy of Subcutaneous Brodalumab for Systemic Sclerosis with Moderate-to-severe Skin Thickening: A Single-arm, Open-label, Multi-dose, Phase 1 Trial [abstract]. Arthritis Rheumatol. 2021; 73 (suppl 9). https://acrabstracts.org/abstract/pharmacokinetics-safety-and-efficacy-of-subcutaneous-brodalumab-for-systemic-sclerosis-with-moderate-to-severe-skin-thickening-a-single-arm-open-label-multi-dose-phase-1-trial/. Accessed February 2, 2023.
  • Tweet
  • Email
  • Print

« Back to ACR Convergence 2021

ACR Meeting Abstracts - https://acrabstracts.org/abstract/pharmacokinetics-safety-and-efficacy-of-subcutaneous-brodalumab-for-systemic-sclerosis-with-moderate-to-severe-skin-thickening-a-single-arm-open-label-multi-dose-phase-1-trial/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2023 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences